Aim: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation. Materials & methods: Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method. Results: SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression. Conclusion: This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.
Inhaled simvastatin nanoparticles for inflammatory lung disease
Pisano, Elvira;Scalia, Santo;
2017
Abstract
Aim: Current inhaled treatments are not adequate to treat all lung diseases. In this study, a promising nanotechnology has been developed to deliver a potential anti-inflammatory and muco-inhibitory compound, simvastatin, for treatment of inflammatory lung diseases via inhalation. Materials & methods: Simvastatin nanoparticles (SV-NPs) encapsulated with poly(lactic-co-glycolic) acid were fabricated using the solvent and anti-solvent precipitation method. Results: SV-NPs were found to be stable up to 9 months at 4°C in a freeze-dried form prior to reconstitution. The amount of mucus produced was significantly reduced after SV-NPs treatment on inflammation epithelial cell models and were effective in suppressing the proinflammatory marker expression. Conclusion: This study suggests that SV-NPs nebulization could potentially be used for the treatment of chronic pulmonary diseases.File | Dimensione | Formato | |
---|---|---|---|
Editoriale11392_2381127.pdf
solo gestori archivio
Descrizione: versione editoriale
Tipologia:
Full text (versione editoriale)
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
7.32 MB
Formato
Adobe PDF
|
7.32 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Preprint11392_2381127.pdf
accesso aperto
Descrizione: pre print
Tipologia:
Pre-print
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
1.7 MB
Formato
Adobe PDF
|
1.7 MB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.